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Introduction: Leishmaniasis is a reemerging disease that causes 
more sequelae and disability than any other of its kind in areas where 
geographical conditions favor the presence of the vector.
Objective: To describe the behavior, geographical distribution 
and initial clinical management of cutaneous leishmaniasis in the 
department of Boyacá between 2008 and 2015.
Materials and methods: Observational, retrospective study on a 
sample of patients diagnosed with cutaneous leishmaniasis in the 
department of Boyacá, Colombia, registered in the mandatory 
epidemiological notification sheets of the Colombian public health 
surveillance system from 2008 to 2015.
Results: 63.6% of patients were men with occupations related to 
forestry activities and from rural areas. 81% of the reported cases 
were located in western Boyacá, along the Magdalena River basin, 
one of the main tributaries of Colombia. Inadequate initial clinical 
management was observed in 25% of the study sample, which is a 
risk factor for resistance to pentavalent antimonials.
Conclusion: It is necessary to implement follow-up strategies for 
patients with cutaneous leishmaniasis in order to verify the cure 
criteria for the disease and propose strategies for its prevention in 
the identified populations that are at greater risk.
Keywords: Leishmania; Colombia; Chemotherapy; Public Health; 
Geographic Information Systems (MeSH).
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| Resumen |
Introducción. La leishmaniasis es una de las enfermedades reemergentes 
que más secuelas y discapacidad causa en zonas donde las condiciones 
geográficas favorecen la presencia del vector.
Objetivo. Describir el comportamiento, la distribución geográfica y el 
manejo clínico inicial de la leishmaniasis cutánea en el departamento 
de Boyacá, Colombia, entre los años 2008 y 2015.
Materiales y métodos. Estudio observacional descriptivo de tipo 
retrospectivo cuya muestra correspondió a las fichas de notificación 
epidemiológica obligatoria del Sistema de Vigilancia en Salud Pública 
pertenecientes a pacientes diagnosticados con leishmaniasis cutánea 
en Boyacá del 2008 al 2015.
Resultados. De los afectados, el 63.6% correspondió a hombres 
con ocupaciones afines a actividades forestales y procedentes de 
zonas rurales. El 81% de los casos se localizaron en el occidente del 
departamento junto a la cuenca del Rio Magdalena, uno de los principales 
afluentes del territorio colombiano. Se evidenció un tratamiento clínico 
inicial inadecuado en el 25% de la muestra, lo que constituyó un factor 
de riesgo para resistencia a los antimoniales pentavalentes.
Conclusión. Es necesaria la implementación de estrategias de 
seguimiento a los pacientes con la finalidad de constatar los criterios 
de curación de la enfermedad y plantear estrategias para su prevención.
Palabras clave: Leishmania; Meglumina; Colombia; Quimioterapia; 
Salud Pública; Sistemas de Información Geográfica (DeCS).
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Introduction
Leishmaniasis is an infection caused by an intracellular flagellated 
protozoan transmitted by the bite of hematophagous mosquitoes belonging 
to the family Psychodidae, genera Phlebotomus and Lutzomyia. (1) 
Around 20 Leishmania species have a pathogenic potential for humans, 
and also have the ability to infect mammals of different species and 
generate both cutaneous and visceral involvement. (2-4)
Leishmaniasis is considered an endemic pathology in around 
70 countries; however, notifying it as an event in public health is 
mandatory only in 32 of them, which is why its actual incidence is 
underestimated. (5) The World Health Organization estimates about 
1.3 million new cases and 20 000 to 30 000 deaths per every year, 
mostly due to visceral involvement. (6) Cutaneous leishmaniasis is 
the most common form of the disease and occurs in exposed body 
regions causing ulcerative lesions and poor healing processes. (7,8) 
95% of the events related to this form occur in the Americas, the 
Middle East and Central Asia, being Afghanistan, Iran, Algeria, Syria, 
Brazil and Colombia the most affected countries. (6)
In Colombia, the incidence of leishmaniasis is high and exceeds 
12 000 cases per year; its geographical distribution involves a large 
part of the country. (9-11) The species L. panamensis, L. guyanensis, 
L. braziliensis, L. amazonensis and L. mexicana have been associated 
with the cutaneous and mucocutaneous form of the disease and are 
responsible for most cases. (12,13)
According to the epidemiological bulletin of the  Instituto Nacional 
de Salud (National Institute of Health) of Colombia, Boyacá ranks 
ninth countrywide regarding new cases documented in 2016, which 
is above the national average, being the municipalities of Otanche, 
San Pablo de Borbur, Pauna, Quípama and Puerto Boyacá the places 
with the highest number of cases reported. (14,15) This distribution 
puts the department at a medium risk for the occurrence of the event.
Currently, several pharmacological treatments are available in the 
guidelines of the Instituto Nacional de Salud to manage leishmaniasis 
optimally, which range from local therapies to systemic medications. 
(16,17) However, there is no single drug that effectively treats all 
Leishmania species, nor the conditions they cause. (4,18) Furthermore, 
the development of new compounds is limited because the most 
affected population is under poverty conditions and, in turn, have 
greater difficulty for accessing health services. With this in mind, the 
implementation of new drugs may represent a high acquisition cost, 
thus affecting mostly this type of population. (19)
Pentavalent antimonials used as pharmacotherapy to treat 
cutaneous leishmaniasis continue to be the first management option. 
(16,20) Meglumine antimonate is the most used and is recommended 
in the guidelines of the Instituto Nacional de Salud as the first option 
for the management of this disease in Colombia. (3,21,22) The average 
dose is 20 mg/k once a day, though local or systemic application for 
20 or 30 days, depending on the route of administration of the drug, 
being shorter in the case of systemic therapy and longer in the case 
of local application. (3,19)
It is possible to observe therapeutic failures caused by low 
adherence, drug resistance and the use of subtherapeutic doses, which, 
in turn, are related to three factors: lack of knowledge on the part 
of the treating health personnel about the doses and presentation of 
the drugs; lack of dose adjustment according to the patient’s weight 
during the treatment; and lack of follow-up. (19) Moreover, another 
factor is treatment abandonment due to local side effects such as 
pain at the site of application, arthralgias, myalgias and even organic 
involvement manifested through liver and kidney failure and disorders 
in the electrical conduction system of the heart, which in some cases 
may seriously compromise the health of patients. (8,23)
This study aimed to make an epidemiological approach, not only 
to the distribution of the disease in Boyacá, but to its behavior and 
the factors that determine its occurrence in the affected population. 
In short, the objective is to describe the behavior, geographical 
distribution and initial clinical management of cutaneous leishmaniasis 
in the department of Boyacá between 2008 and 2015. 
Materials and methods
A descriptive, retrospective study was carried out. Considering that 
the event is notifiable, the information generated on a regular basis 
through the notification form of the Epidemiological Surveillance 
System (SIVIGILA by its acronym in Spanish) allowed obtaining 
data on sociodemographic, clinical and geographical distribution 
conditions of the patients diagnosed with cutaneous leishmaniasis. 
The study included users who were reported to SIVIGILA as 
confirmed cases of cutaneous leishmaniasis in the 123 municipalities 
of Boyacá between 2008 and 2015 and had complete epidemiological 
records. Patients that acquired the infection in a department other 
than Boyacá were excluded.
The analyzed variables were age, sex, weight, occupation, place 
of occurrence of the case, health insurance system, ethnicity, place 
of origin, number and location of cutaneous leishmaniasis lesions, 
previous  hospitalization, previous treatment, estimated dose per day 
and total number of vials administered. 
Statistical analysis
Statistical analysis of demographic and clinical conditions was 
performed using the IBM SPSS program (Chicago, Illinois) version 
23. Univariate and bivariate analyses of the aspects established in the 
categorization of the variables were carried out. Qualitative variables 
such as sex, geographic area, ethnicity, health insurance system, 
among others, were analyzed using absolute and relative frequencies. 
On the other hand, quantitative variables were processed through 
measures of central tendency.
An analysis was made taking into account the geographical 
distribution of the cases reported in Boyacá between 2008 and 2015. 
A color scale was used: green for municipalities with 1 to 8 cases, 
yellow for 9 to 16 cases, orange for 17 to 24 cases and red more than 
25 cases. To elaborate the maps with the geographic distribution of the 
patients affected by cutaneous leishmaniasis, the EpiMap extension 
of EpiInfo was used.
Regarding clinical management of patients, criteria for locating 
the lesions were determined by means of frequency analysis. This 
was confirmed by weight and the amount of doses in milligrams —if 
the patients received an adequate initial dose—, and the amount of 
vials during the chemotherapy period established according to the 
protocol of the Instituto Nacional de Salud (National Health Institute) 
of Colombia. Data were obtained from calculating the initial dose 
per day adjusted by weight for each patient. Then, the number of 
vials that should be administered during the 20 days of treatment 
was established taking into account that the excess content of each 
vial per day should be discarded and compared with the estimated 
initial dose recorded in the notification form and the total amount of 
vials administered to each patient.
Ethical considerations
This study was elaborated following the guidelines of the Council for 
International Organizations of Medical Sciences. This research is risk-
free according to Resolution 8430 of 1993 of the Ministry of Health 
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Colombia, which establishes scientific, technical and administrative 
regulations for health research. (24) Moreover, confidentiality, respect 
and security of the information were preserved at all times during its 
processing. However, authorization from the Ministry of Health of 
Boyacá, Public Health Surveillance Area, was requested to access 
the databases. The research protocol was presented to the Ethics 
Committee of the Universidad de Boyacá.
Results
Sociodemographic conditions
Out of 949 epidemiological records found, 40 were excluded due to poor 
quality of the data or lack of data. The analysis included 909 files correctly 
entered in the system. The average age was 23 years (σ: 19, min-max: 
4-52), and 429 cases (47.2%) occurred in the 0-18 age range; of these, 
155 cases (17%) occurred in the 0-5 range. The general distribution of 
affected individuals determined by life cycle is shown in Table 1, which 
makes evident that adults (29 to 59 years) were involved in 26.5% of the 
cases. Regarding sex, except for children (6 to 11 years), men (63.6% of 
the total sample) were more involved in this type of cases than women.
According to the place of residence of the patients, three classifications 
were used: municipal head, population center and dispersed settlement, 
the latter being the most affected with 75% of the cases.
Most subjects affected (71.9%) were students, people without a 
specific occupation and workers in rural areas, most of them enrolled in 
the subsidized system (70.5%) of the General System of Social Security 
in Health. The most frequent ethnicity (96.9%) was specified as “other” 
in the compulsory notification sheet, which corresponds to cross-breeding 
between natives and Europeans during colonial times (mestizo).
Table 1. Sociodemographic conditions and age group of patients diagnosed with cutaneous leishmaniasis in Boyacá, Colombia. 2008-2015.
Conditions
Life cycle in years
0-5 % 6-11 % 12-17 % 18-28 % 29-59 % 60-99 % Total %
Population
Women 72 8 80 8.8 48 5.3 42 4.6 68 7.5 21 2.3 331 36.4
Men 83 9.1 61 6.7 85 9.3 132 14.5 173 19 44 4.9 578 63.6
Total 155 17.1 141 15.5 133 14.6 174 19.1 241 26.5 65 7.2 909 100
Occupation
Rural work 0 0 0 0 1 0.1 46 5 104 11.4 36 4 187 20.5
Student 42 4.6 125 13.7 122 13.4 11 1.2 1 0.1 0 0 301 33.1
Domestic 
work
1 0.1 0 0 1 0.1 32 3.5 57 6.3 16 1.6 107 11.8
Mining 0 0 0 0 0 0 4 0.4 16 1.8 2 0.2 22 2.4
Military 0 0 0 0 0 0 53 5.9 14 1.5 0 0 67 7.4
Other 
occupations
1 0.1 0 0 0 0 16 1.8 36 4 6 0.7 59 6.5
Unemployed 111 12.2 16 1.8 9 1 12 1.3 13 1.4 5 0.6 166 18.3




14 1.5 13 1.4 13 1.4 41 4.5 33 3.6 5 0.6 119 13.1
Population 
center
11 1.2 9 1 12 1.3 24 2.6 25 2.7 4 0.4 85 9.3
Dispersed 
settlement
130 14.4 119 13.1 108 11.9 109 12 183 20.2 56 6.2 705 77.6
Total 155 17.1 141 15.5 133 14.6 174 19.1 241 26.5 65 7.2 909 100
Health insurance 
system
Contributive 10 1.1 15 1.6 9 1 17 1.9 45 5 6 0.7 102 11.2
Subsidized 131 14.5 118 13 115 12.6 79 8.7 151 16.6 47 5.2 641 70.5
Exceptional 
system
0 0 0 0 0 0 50 5.5 17 1.9 0 0 67 7.4
No insurance 14 1.5 8 0.9 9 1 28 3 28 3 12 1.3 99 10.9
Total 155 17.1 141 15.5 133 14.6 174 19.1 241 26.5 65 7.2 909 100
Ethnicity
Indigenous 0 0 0 0 0 0 2 0.2 6 0.7 1 0.1 9 1
Gypsy 0 0 0 0 0 0 0 0 1 0.1 0 0 1 0.1
Palenque 2 0.2 0 0 0 0 0 0 0 0 0 0 2 0.2
Afro-
Colombian
7 0.8 1 0.1 3 0.3 3 0.3 1 0.1 1 0.1 16 1.8
Mestizo 146 16.1 140 15.4 130 13.3 169 18.6 233 25.6 63 6.9 881 96.9
Total 155 17.1 141 15.5 133 14.6 174 19.1 241 26.5 65 7.2 909 100
Source: Own elaboration based on the data obtained in the study.
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Geographical distribution
When analyzing notifications issued during the 8-year period under 
study, a varied behavior was observed, showing two major peaks in 
2010 with 187 cases and 2014 with 173 cases, in contrast to 2011, 
when only 58 cases were recorded (Figure 1).
Figure 1. Number of cutaneous leishmaniasis cases reported per year in 
Boyacá, Colombia. 2008-2015. 
Source: Own elaboration based on the data obtained in the study.
Figure 2 shows the behavior in the municipalities that reported 
cases of cutaneous leishmaniasis during the study period. This 
information allowed to determine that 5 of the 123 municipalities 
of the department presented the highest number of cases, being the 
municipality of Otanche the one that reported the highest prevalence 
with 344 cases (37.8%), followed by San Pablo de Borbur with 139 
(15.3%). It should be noted that these five municipalities account for 
81% of the total cases reported during the study period.
According to the geographical distribution analysis, the municipalities 
with the highest number of cases are located in the western province 
during the entire period, especially in the municipalities of Otanche, 
San Pablo de Borbur, Puerto Boyacá and Pauna. The maps also show 
some cases of municipalities that have no risk for the event, among them 
Chiquinquirá, Chita, Duitama, El Cocuy, Nobsa, Panqueba, Saboya, 
Sogamoso, Tibasosa and Ventaquemada (Figure 3).
Figure 2. Municipalities with reports of patients with leishmaniasis in 
Boyacá, Colombia. 2008-2015. 
Source: Own elaboration based on the data obtained in the study.
Initial clinical management
The number of cutaneous leishmaniasis lesions is variable: 665 cases 
(73.1%) had a single lesion; 179 (19.7%) had two; 57 (6.3%) had 
three and 8 (0.8%) had four or more. The presence of lesions was 
greater in upper and lower limbs with a total of 482 (53%) and 333 
(36.6%) cases, respectively. 247 (27.2%) patients had lesions on the 
face and 162 (17.8%) on the trunk. The sum of injuries is greater 
than the number of patients because some individuals were affected 
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Figure 3. Geographical distribution of cutaneous leishmaniasis cases in Boyacá, Colombia. 2008-2015. 
Continues.
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Figure 3. Geographical distribution of cutaneous leishmaniasis cases in Boyacá, Colombia. 2008-2015. 
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Figure 3. Geographical distribution of cutaneous leishmaniasis cases in Boyacá, Colombia. 2008-2015. 
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Figure 3. Geographical distribution of cutaneous leishmaniasis cases in Boyacá, Colombia. 2008-2015. 
Source: Own elaboration based on the data obtained in the study.
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Initial clinical management
The number of cutaneous leishmaniasis lesions is variable: 665 cases 
(73.1%) had a single lesion; 179 (19.7%) had two; 57 (6.3%) had three 
and 8 (0.8%) had four or more. The presence of lesions was greater 
in upper and lower limbs with a total of 482 (53%) and 333 (36.6%) 
cases, respectively. 247 (27.2%) patients had lesions on the face and 162 
(17.8%) on the trunk. The sum of injuries is greater than the number of 
patients because some individuals were affected by injuries that involve 







































































Not adjusted by weight Adjusted by weight Total
The percentage of patients infected and previously hospitalized 
due to leishmaniasis was 3%. Similarly, a history of previous 
treatment was found in 9.6% of the total of patients included in 
this study. Figure 4 shows the number of subjects who received 
adequate and inadequate treatment regarding the therapeutic dose 
according to the weight in kilograms discriminated per year. Of 
the total cases, 73.9% received the number of vials required 
according to their weight during the study period. The lowest rate 
of error in the calculation of the initial dose (12%) was observed 
in 2015.
Figure 4. Pharmacological treatment with meglumine antimonate, calculated according to the guidelines of 
the Colombian Ministry of Health and Social Protection and discriminated by year in patients with cutaneous 
leishmaniasis from Boyacá, Colombia. 2008-2015. 
Source: Own elaboration based on the data obtained in the study.
Discussion
The results of this study indicate that leishmaniasis is a disease that 
affects young people, residents of rural areas, who work in forested 
areas, which coincides with Cella et al. (25) and Bsrat et al. (26) 
Regarding sex, it was more frequently observed in men, which is 
similar to the reports found in the works carried out by Cella et al. 
(25), Soares et al. (27), Aguado et al. (28) and Cota et al. (29)
As in the studies of Cota et al. (29) and Pontello et al. (30), the 
body areas most affected by cutaneous leishmaniasis are the upper 
and lower limbs. The number of predominant lesions in the subjects 
of this study was one injury, which coincides with Blanco et al. (31).
Regarding geographical distribution, a high number of cases was 
observed in the western province, especially in the municipalities 
of Otanche, San Pablo de Borbur, Puerto Boyacá and Pauna, which 
have been classified by other studies as critical sites for the presence 
of vectors infected by the Leishmania parasite. (32)
Pentavalent antimonials were the drugs used in the patients included 
in this study, mainly meglumine antimoniate. Some findings include 
inadequate dosing in over 25% of the cases due to deficiencies in the 
calculation of the initial dose of the treatment. Such situation may 
have a negative impact on the health of patients since it is considered 
a risk factor for resistance to the action of the compounds used in the 
management of leishmaniasis. (33,34) Inadequate pharmacological 
therapy for this pathology is a widely recognized problem in the 
current medical literature; however, there are no studies to compare 
our results in this regard, since no research addresses the initial clinical 
management performed on patients affected by cutaneous leishmaniasis. 
Mohapatra (33) states that the lack of knowledge of physicians about 
the presentation, dose and duration of treatment is one of the main 
causes of resistance to antileishmanial drugs in developing countries.
This study did not include any follow-up information regarding 
the treatment of patients because data were taken from the SIVIGILA 
notification sheets and there are no sections that allow for a 
clinical follow-up or cure criteria; therefore, it was impossible to 
assess the efficacy of pharmacological management and verify the 
healing process of patients whose cases were notified as confirmed 
leishmaniasis. Furthermore, there was no record of the doses applied 
to patients per day, which is decisive for the management of this 
pathological entity, since a 20-day duration and not proving its 
application may lead to failures during the administration of the 
treatment and complications such as drug resistance.
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One of the limitations of this study is the lack of an instrument 
for monitoring the clinical picture of patients affected by cutaneous 
leishmaniasis in Boyacá, Colombia. In spite of that, this study aimed 
at updating the existing information regarding the epidemiological 
behavior and geographical distribution of leishmaniasis in Boyacá. 
In addition, a description of the initial pharmacological treatment was 
established to provide recommendations to health decision-makers 
at the regional and national levels in order to correct inadequate 
behaviors and encourage other authors to study vector-borne diseases 
in greater depth. There are still shortcomings in the identification and 
management of these cases, which constitutes a problem of interest 
for public health.
Conclusions
Findings related to the type of presentation and behavior of the disease 
are similar to other works, which lead to believe that its behavior is as 
expected. West Boyacá is the region most affected by leishmaniasis 
in the department; five of the municipalities in this area are classified 
as critical due to the high presence of infected vectors, which may 
be related to the geographical location and the influence of fluvial 
sources. This last point must be taken into account when developing 
strategies for the epidemiological control of the disease. 
Regarding initial management, and in spite of the guidelines for 
diagnosis and management, the lack of knowledge of the treating 
medical personnel has led to inadequate management in 1 of every 4 
patients diagnosed who have been treated with subtherapeutic doses, 
causing failures that result in recurrences. 
Once again, there is a need to create a public health surveillance 
instrument that not only collects report data but also adherence 
monitoring and medication administration, as well as the occurrence 
and management of collateral effects and complications of the disease. 
Regulating entities should detect failures in the notification files 
of the disease, because when a clinical and pharmacological follow-
up is required, it is necessary to modify these documents to improve 
surveillance and control processes of cutaneous leishmaniasis. 
Efficient training of the treating medical personnel and the health 
team that interacts with these patients is essential to reduce the rates 
of treatment failure.
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